Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Opdivo Fallout: Rivalry In PD-1 Market To Continue, More Trials Could Mean More Failures

Executive Summary

Opdivo's Phase III disappointment in first-line non-small cell lung cancer (NSCLC) is not the end of the world for Bristol-Myers Squibb, according to Datamonitor Healthcare analyst Dustin Phan. It also may not be the last surprise in a field with so many contenders and so many ongoing trials, as data from Pharmaprojects shows.

Advertisement

Related Content

Roche Raises IO Credentials On Tecentriq Lung Cancer Data
Surprise! It’s A Phase III Failure
Opdivo's Failure In First-Line Lung Cancer Prompts Rethink On Trial Endpoints
Merck Poised To Be First To Market With A PD-1 For First-Line Lung Cancer

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097106

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel